New drug combo shows promise for tough head and neck cancers
NCT ID NCT05057247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, duvelisib and docetaxel, in 26 people with head and neck cancer that had returned or spread and could not be cured. The goal was to see if the combination could shrink tumors or slow the disease. The approach aims to control the cancer rather than cure it, as ongoing treatment is typically needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Drug combo aims to stall head and neck Cancer's return
- Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
- Promising new combo targets tough head and neck cancer
- New combo therapy aims to tame recurrent head and neck cancer
- AI-Designed mRNA vaccine takes on advanced tumors in first human test
- New drug cocktail targets Hard-to-Treat cancers